**Suppl 1.** The Stratified Study Outcomes of Counting Cox model

|  |  |  |  |
| --- | --- | --- | --- |
|  | Observation period (days) | Event number | Adjusted HR (95% CI) |
| **Gender** | | | |
| **Male** | | | |
| LABA+LAMA | 1920356 | 1170 | 1 (reference) |
| Triple therapy | 4502748 | 3036 | 1.176 (1.100-1.258) |
| **Female** | | | |
| LABA+LAMA | 570320 | 363 | 1 (reference) |
| Triple therapy | 2852537 | 1969 | 1.103 (0.989-1.230) |
| **Age** | | | |
| **<65 years old** | | | |
| LABA+LAMA | 975417 | 506 | 1 (reference) |
| Triple therapy | 3470829 | 2035 | 1.089 (0.974-1.218) |
| **≥65 years old** | | | |
| LABA+LAMA | 1515259 | 1028 | 1 (reference) |
| Triple therapy | 3884456 | 3070 | 1.072 (1.072-1.257) |
| **Disease severity (times of COPD exacerbations)** | | | |
| **0** | | | |
| LABA+LAMA | 2454719 | 856 | 1 (reference) |
| Triple therapy | 7022445 | 2709 | 1.148 (1.061-1.241) |
| **1** | | | |
| LABA+LAMA | 256203 | 160 | 1 (reference) |
| Triple therapy | 778303 | 516 | 1.007 (0.839-1.208) |
| **≥2** | | | |
| LABA+LAMA | 263515 | 233 | 1 (reference) |
| Triple therapy | 723973 | 817 | 1.176 (1.013-1.365) |
| **Disease duration** | | | |
| **less than 3 months** |  |  |  |
| LABA+LAMA | 1515259 | 432 | 1 (reference) |
| Triple therapy | 3884456 | 1192 | 1.011 (0.904-1.131) |
| **3-6 months** | | | |
| LABA+LAMA | 677274 | 260 | 1 (reference) |
| Triple therapy | 1921643 | 929 | 1.246 (1.083-1.434) |
| **more than 6 months** | | | |
| LABA+LAMA | 1426765 | 557 | 1 (reference) |
| Triple therapy | 4272685 | 1921 | 1.159 (1.053-1.277) |
| COPD, chronic obstructive pulmonary disease. LABA, long-acting beta2-agonist. LAMA, long-acting muscarinic antagonist. | | | | |